Genetics and Epigenetics of Recurrent Hydatidiform Moles: Basic Science and Genetic Counselling by Ngoc Minh Phuong Nguyen & Rima Slim
MANAGEMENT OF GESTATIONALTROPHOBLASTIC DISEASES (A.N.Y. CHEUNG, SECTION EDITOR)
Genetics and Epigenetics of Recurrent Hydatidiform Moles:
Basic Science and Genetic Counselling
Ngoc Minh Phuong Nguyen & Rima Slim
Published online: 21 January 2014
# Springer Science+Business Media New York 2014
Abstract Gestational trophoblastic disease (GTD) is a group
of condi t ions that or iginate from the abnormal
hyperproliferation of trophoblastic cells, which derive from
the trophectoderm, the outer layer of the blastocyst that would
normally develop into the placenta during pregnancy. GTDs
encompass hydatidiform mole (HM) (complete and partial),
invasive mole, gestational choriocarcinoma, placental-site tro-
phoblastic tumor, and epithelioid trophoblastic tumor. Of the-
se, the most common is HM, and it is the only one that has
been reported to recur in the same patients from independent
pregnancies, which indicates the patients’ genetic predisposi-
tion. In addition, HM is the only GTD that segregates in
families according to Mendel’s laws of heredity, which made
it possible to use rare familial cases of recurrent HMs (RHMs)
to identify two maternal-effect genes, NLRP7 and KHDC3L,
responsible for this condition. Here, we recapitulate current
knowledge about RHMs and conclude with the role and
benefits of testing patients for mutations in the known genes.
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Introduction
Hydatidiform mole (HM) is an aberrant human pregnancy
with abnormal embryonic development. It occurs once in
every 600 pregnancies in Western countries [1] but at higher
rates in the Middle East, Latin America, Africa, and the Far
East [2–4]. Sporadic moles have a multifactorial etiology
involving various combinations of several environmental
and genetic factors. Among women with one HM, 10 % to
20 % have other forms of reproductive loss, mainly as spon-
taneous abortions [5–8]. Because the frequency of two repro-
ductive losses (one HM and one spontaneous abortion) in
these patients (10–20 %) is 2–4 times higher than the frequen-
cy of two spontaneous abortions in the general population (2–
5 %) [9–11], it is believed that some of these patients have
genetic predisposition to recurrent reproductive loss.
Recurrent hydatidiform moles are defined by the occur-
rence of at least two molar pregnancies in the same patient.
The earliest report of RHMs available to us through PubMed
search is byMack and Catherwood in 1930 [12]. In this paper,
the authors describe one case of 10 RHMs, review the litera-
ture for cases of RHMs, and cite a report in 1912 by Essen-
Moeller of a patient with 18 RHMs. The frequency of RHMs
varies among populations and countries. InWestern countries,
studies by several groups from various countries have shown
that 1% to 2% of patients with a prior mole have a second one
[5, 13, 14]. However, higher frequencies of RHMs are report-
ed from the Middle and Far East; in these regions, the fre-
quency of RHMs ranges from 2.5% up to 9.4 % [6, 15–18]. In
rare cases, RHMs have been seen in related women from the
same family, and these cases are termed familial cases of
RHMs. Such cases are considered very rare, and their frequen-
cy is not known.
At the clinical level, patients with RHMs do not have any
particular feature that distinguishes them from those with
nonrecurrent sporadic moles [19], which highlights the
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importance of DNA testing to determine patients who are at
risk for mole recurrence. Also, current data indicate that
determining the parental contribution to the molar tissues
can help detect patients at higher risk for mole recurrence. In
this review, we summarize known data about RHMs and
highlight the benefits of DNA testing.
NLRP7
NLRP7, a nucleotide oligomerization domain (NOD)-like r-
eceptor, pyrin containing 7, maps to 19q13.4 and is the first
identified causative gene for RHMs [20]. Studies from various
groups and populations concur thatNLRP7 is a major gene for
this condition and is mutated in 48–80 % of patients with at
least two HMs, depending on patients’ ascertainment criteria
and populations [21–24]. To date, 47 mutations in NLRP7
have been reported in patients with two defective alleles
(Fig. 1a) ([25] and http://fmf.igh.cnrs.fr/ISSAID/infevers/).
These mutations include stop codons, small deletions or
insertions (less than 20-bp), splice mutations, large deletions
or insertions, and complex rearrangements. In addition to
these mutations, two protein-truncating mutations, a stop co-
don, L823X [21], and a deletion of 60-kb extending from
intron 8 of NLRP7 to intron 11 of NLRP2 [26] and approxi-
mately 17 missenses have also been seen as single heterozy-
gous mutations or variants in patients with recurrent and
sporadic moles (Fig. 1a) [26–31]. However, the pathological
significance of these single mutations or variants is still the
subject of debate, and more data are needed to reach a con-
clusion on their potential involvement in the causation or
genetic susceptibility for moles. NLRP7 transcripts have been
identified in several human tissues, including endometrium,
placenta, hematopoietic cells, all oocytes stages, and preim-
plantation embryos. NLRP7 transcripts decrease after fertili-
zation and during preimplantation development to reach their
lowest level at day 3 of embryonic development, which cor-
responds to the blastocyst stage, and then increase sharply
from day 3 to day 5, which coincides with the transcriptional
activation of the embryonic genome.
Functional Roles of NLRP7
NLRP7 codes for 1037 amino acid protein (including all
coding exons of all splice isoforms) and has three main
domains: pyrin, NACHT (i.e., found in the NAIP, CIITA,
HET-E, and TP1 family proteins) and 10 leucine-rich repeats
(LRR). NLRP7 is a member of the NLR family of proteins
with a role in inflammation and apoptosis. Below, we outline
known roles of NLRP7 in various cellular models and discuss
their potential involvement in the pathophysiology of recur-
rent moles.
Overexpressed NLRP7 Downregulates Intracellular IL-1β
Emerging data from three different groups about the role of
NLRP7 indicate that its overexpression in transient transfec-
tions downregulates the production of IL-1β, an important
mediator of the inflammatory response. The first study by
Kinoshita et al. demonstrated that overexpressed
NLRP7 interacts with overexpressed pro-IL-1β and
pro-caspase-1 and downregulates caspase-1-dependent
IL-1β secretion in HEK293 cells by inhibiting pro-IL-
1β processing [32]. Another study by Messaed et al.
confirmed the inhibitory effect of overexpressed NLRP7
on IL-1β, but showed that NLRP7 acts primarily on pro-
IL-1β and inhibits its intracellular synthesis [33•]. In addition,
this study showed that NLRP7 inhibitory function is mediated
concomitantly by its three domains, and mostly by the LRR.
Although the precise mechanism by which NLRP7
downregulates intracellular IL-1β (pro- or mature) is not fully
understood, NLRP7 has been shown to interact physically
with IL-1β, caspase-1, and ASC, with the latter mediated by
the pyrin domain [32, 34].
Physiological Level of NLRP7 Inhibits IL-1β Secretion
in Monocytic Cells
Using an ex vivo cellular model, Messaed et al. also looked at
the consequences of NLRP7mutations on IL-1β secretion by
peripheral blood mononuclear cells (PBMCs) from patients
with NLRP7 mutations [33•]. They showed that patient cells
secrete lower levels of IL-1β than control cells despite the fact
that these same cells have normal or slightly higher amounts
of intracellular pro-IL-1β synthesis, indicating NLRP7’s role
in IL-1β secretion into the extracellular milieu. These findings
are in line with those obtained by Kinoshita et al. in stable
transfections of THP-1 cells (of human monocytic origin),
where expressing an N-terminal 35-kDa NLPR7 fragment,
which mimics some protein-truncating mutations observed
in patients with RHMs, reduced IL-1β secretion. This finding
was also confirmed in a third cellular model described by
Khare et al., who demonstrated that NLRP7 knockdown
using small interfering RNA in macrophages significant-
ly impairs IL-1β release upon stimulation with microbi-
al acylated lipopeptides [34]. Within monocytic cells,
NLRP7 co-localizes with the Golgi and microtubule-
organizing center and associates with microtubules.
This suggests that NLRP7 mutations may decrease cyto-
kine secretion by affecting the structure of cytoskeletal
microtubules, either directly or indirectly, and impairing the
trafficking of IL-1β-containing vesicles [33•]. This suggestion
is further supported by the fact that treating hematopoietic
cells with nocodazole, a microtubule depolymerizing agent,
fragmented NLRP7’s signal [33•].
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An Interesting Emerging Role for NLRP7 in Trophoblast
Differentiation
Another novel and interesting role for NLRP7 was recently
demonstrated by Mahadevan et al. In this study, the authors
showed that NLRP7 knockdown in human embryonic stem
cells led to an earlier expression of two trophoblast differen-
tiation markers, GCM1 and INSL4, suggesting that NLRP7
loss of function accelerates trophoblast differentiation [35•].
Another interesting finding in this study was that NLRP7
knockdown increased the level of human chorionic gonado-
tropin (hCG), known to be very high in patients with molar
pregnancies. This new role of NLRP7 is very important in
view of the fact that hydatidiform mole is characterized by
hyperproliferation of the trophoblast and production of high
levels of hCG.
Possible Roles of NLRP7 in the Pathology of Moles
The known functions of NLRP7 in inflammatory signalling of
hematopoietic cells raise questions as to whether NLRP7’s
role in IL-1β production may be the cause of the early em-
bryonic development arrest observed in molar pregnancies.




























































































Fig. 1 Schematic representations of NLRP7 and KHDC3L protein struc-
tures with identified mutations and non-synonymous variants in patients
with hydatidiform moles and reproductive loss. (a) NLRP7 protein struc-
ture with its domains. PYD = pyrin domain; NACHT == domain present
in NAIP, CIITA, HET-E, and TP1 family proteins; ATP = 5′-triphosphate
binding motif; LRR = leucine-rich repeats. The ATP binding domain is a
small motif of 8 amino acids and starts at position 178. (b) KHDC3L
protein structure with identified mutations and non-synonymous variants.
KH stands for K homology domain. Mutation nomenclature is according
to the Human Genome Variation Society guidelines (http://www.hgvs.
org/mutnomen/recs.html). Mutations found in patients with two defective
alleles are in red. Non-synonymous variants (NSVs) found only in
patients in heterozygous state and not in controls are in blue. NSVs
found in patients and in subjects from the general population are in
black. Mutations found in patients who had at least one live birth are
underlined
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ovulation, and oocyte maturation. For instance, in several
mammalian species, intra-follicular injection of IL-1β in-
creases the rate of ovulation, but decreases the quality of the
oocytes and, consequently, the rate of normal embryonic
development [36, 37]. However, this role for IL-1β in oocytes
is in contradiction with data on cells from patients withNLRP7
mutations, which secrete lower amounts of IL-1β. In addition,
mice lacking IL-1β [38] or Type 1 IL-1 receptor (Il1r1) [39]
are fertile, indicating that the lack of IL-1β signalling does not
significantly affect fertility and embryo viability in mice. In
addition to its role in IL-1β secretion, NLRP7 has been shown
to promote cellular proliferation and invasion in testicular and
endometrial cancer, respectively.
In conclusion, we believe that, individually, none of the
above-described roles of NLRP7 may explain the pathology of
moles or recapitulate all of their features, as it is impossible to
model a pregnancy in any cellular assay. Perhaps a combination
of the above-described functions, with some acting in the oo-
cytes and affecting the differentiation and proliferation of em-
bryonic and trophoblastic tissues, and others acting in hemato-
poietic inflammatory cells present in the endometrium and
downregulating the maternal immune response, together con-
tribute to the three fundamental aspects of moles: retained
human pregnancies with no embryo and excessive trophoblastic
proliferation. We believe that the role of NLRP7 in downregu-
lating maternal inflammation (intra- or extracellular) and the
inability of patients to spontaneously eliminate these unviable
pregnancies is a fundamental aspect of this disease that distin-
guishes it from all other forms of early foetal loss. Indeed, it is
the retention of these early arrested pregnancies that has homog-
enized and distinguished this category of foetal loss from all
other forms of early spontaneous abortions and has consequent-
ly facilitated the identification of two of its causative genes.
KHDC3L
KHDC3L (KH domain containing 3-like), which was identi-
fied in 2011, is a second recessive gene responsible for RHMs
[40•]. KHDC3L maps to chromosome 6, and available data
indicate that this gene is a minor gene for RHMs, accounting
for 10–14% of patients who do not have mutations inNLRP7.
To date, four mutations in KHDC3L have been reported in
patients with two defective alleles (Fig. 1b) [40•, 41].
KHDC3L transcripts have been identified in several human
tissues, including all oocytes stages, preimplantation embryos,
and hematopoietic cells.KHDC3L codes for a small protein of
217 amino acids belonging to the KHDC1 (KH homology
domain containing 1) protein family, members of which con-
tain an atypical KH domain that does not bind RNA as
opposed to proteins with canonical KH domain. In humans,
this family includesKHDC3L,KHDC1,DPPA5 (developmen-
tal pluripotency associated 5), and OOEP (oocyte-expressed
protein) [42]. Expression of KHDC3L is highest in oocytes at
the germinal vesicle stage and then decreases during preim-
plantation development and becomes undetectable at the blas-
tocyst stage [40•], similar to the expression prolife of NLRP7
[43]. In addition, KHDC3L co-localizes with NLRP7 to the
microtubule organizing center and the Golgi apparatus in
lymphoblastoid cell lines [41], which suggests that the two
genes may have similar or overlapping functions in oocyte
and early embryonic development.
RHMs Caused by Mutations in NLRP7 or KHDC3L
are Mostly Diploid Biparental
Common sporadic nonrecurrent CHMs are mostly diploid
androgenetic. Among them, approximately 80 % are
monospermic and the remaining are dispermic. Common
sporadic PHMs aremostly triploid dispermic. Deviations from
these common genotypes, such as monospermic triploidy,
digynic triploidy, triandric tetraploidy, biparental tetraploidy,
and biparental diploidy, have also been reported among both
complete and partial moles but account for a minority of cases,
estimated at about 8 % of common moles [44, 45]. This is not
the case, however for molar tissues from patients with NLRP7
or KHDC3Lmutations. In patients with two NLRP7 defective
alleles, the parental contribution to approximately 81 HM
tissues has been reported, and all were found to be diploid
biparental with the exception of two, which were found to be
triploid dispermic [26] and triploid digynic [46] (Table 1). The
same applies to patients with two KHDC3L defective alleles.
Among these patients, the parental contributions to nine HM
tissues have been determined, and all of themwere found to be
diploid biparental [23, 41, 47, 48] with the exception of one
HM tissue that was found to be triploid digynic [46] (Table 1).
Among patients with a single heterozygous NLRP7muta-
tion or very rare variants not seen in controls, parental contri-
bution to 15HM tissues has been reported. Of these, four were
found to be diploid biparental [26], seven were found to be
diploid androgenetic monospermic [21, 27, 30], and four were
found to be triploid dispermic [22] (Table 1). With respect to
KHDC3L, no molar tissues from patients with single hetero-
zygous variants have been characterized.
Genomic Imprinting in Diploid Biparental Moles
Altered DNA Methylation at Imprinted Genes
in the Conceptions of Patients with KHDC3L or NLRP7
Mutations
Genomic imprinting refers to epigenetic modifications such as
DNA methylation, histone modification, or/and chromatin
remodeling that lead to the expression of only one of the
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two parental copies of a gene. The involvement of genomic
imprinting in the pathology of hydatidiform moles emerged
soon after the demonstration that sporadic complete moles are
androgenetic, which made them an important experimental
tool in characterizing the expression and/or methylation of
imprinted genes [49–51]. Later, the identification of recurrent
familial moles that have the same histopathological features as
the sporadic androgenetic moles [52] and the finding that
these moles are diploid biparental [53] entertained the plausi-
ble and interesting idea that the causative gene for recurrent
moles would be responsible for setting or maintaining the
maternal imprints in the oocytes. To date, four studies have
examined the DNA methylation of imprinted genes in a total
of eight diploid biparental hydatidiform moles from patients
with two defective alleles in KHDC3L or NLRP7 [23, 47, 54,
55]. The first study demonstrated, in one diploid biparental
CHM from a patient with two KHDC3L defective alleles, the
loss of methylation marks at six of seven analyzed differen-
tially methylated regions (DMR) that are normally maternally
methylated, and the gain of methylation marks on one pater-
nallymethylatedDMR (NESP55) that acquires its methylation
at the blastocyst stage (Table 2). In contrast, the methylation at
theH19DMR, which is normally established in the male germ
line, was normal. Two additional diploid biparental moles
from the same patient were later studied, but unfortunately at
different DMRs, and their analysis showed the same trend of
abnormal methylation with the exception of one gene, PEG10,
which preserved its normal methylation on the maternal allele
(Table 2) [23]. Other studies also examined the methylation
status of DMRs in moles from patients with two NLRP7
defective alleles and reported abnormal loss and gain of meth-
ylation at some of them [23, 54, 55]. In one of these studies,
single nucleotide polymorphisms were used to distinguish
parental alleles at some imprinted genes and showed that the
abnormal methylation, indeed, affected the maternal alleles
[54] (Table 2). In conclusion, these data demonstrated the
presence of imprinting abnormalities in diploid biparental
moles from patients with KHDC3L or NLRP7 mutations and
Table 1 Summary of molar genotypes from patients with NLRP7 and KHDC3Lmutations
Diploid biparental Diploid androgenetic Triploid dispermic Triploid digynic References
NLRP7mutations
2 defective alleles 81 (98 %) 0 (0 %) 1 (1 %) 1 (1 %) [21, 23, 26, 27, 30, 46, 55, 65–72]
1 defective allele 4 (33 %) 5 (42 %) 3 (25 %) 0 (0 %) [21, 26, 27, 30, 73]
KHDC3Lmutations
2 defective alleles 8 (100 %) 0 (0 %) 0 (0 %) 0 (0 %) [23, 41, 47]
Table 2 Recapitulation of methylation analysis data in diploid biparental molar tissues from patients with NLRP7 or KHDC3Lmutations
DMR Chr KHDC3L NLRP7 Conclusion
Reference [47] [23] [54] [55] [23]
Patient ID L1 4 & 6 HM70 & HM73 S4
Number of HMs (n) n=1 n=2 n=2 n=2 n=1
Maternal methylated
KCNQ1OT1a 11 − − − − − − − − − − − − − − −
SNRPNb 15 − − − −, − − − − − − − −
PEG1 7 − − − − − −
PEG3 19 − − − − − − − − − − − −
GNAS-1A a 20 − − − − − − − − −
GNAS-AS 20 − − − Complex Inconcl.
GNAS-XLαS b 20 Normal Normal Normal
ZACa 6 − − − − − − − − −
PEG10 a 7 Normal, − − Normal Normal
Paternally methylated
H19 a 11 Normal +, ++ Normal Inconcl.
GNAS-NESP55b 20 +++ +++ +++ +++ c +++ +++
Chr, chromosome; a primary imprint; b secondary imprint ; c gain of methylation at this locus was found in the two diploid biparental moles as well as in
one normal term placenta and in one androgenetic mole; Inconcl., inconclusive. Different results on two HM tissues are separated by a comma
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indicated that these abnormalities may have occurred during
oogenesis and/or early embryogenesis. Because NLRP7 and
KHDC3L proteins do not have DNA binding domains or any
domain that is found in DNA methyltransferases, it was not
clear whether these methylation defects play a primary causal
role in the oocytes leading to the formation of moles or
whether they are a secondary consequence of abnormal
postzygotic development.
Altered DNA Methylation Beyond Non-Imprinted Genes
To investigate the role of NLRP7 in establishing methylation
marks at imprinted genes,Mahadevan et al. recently examined
the consequences of NLRP7 knockdown on the DNA meth-
ylation of imprinted genes during the differentiation of human
embryonic stem cells (hESCs) into trophoblast cells [35•].
However, they did not observe any DNAmethylation changes
at imprinted DMRs, including those that were previously
shown to be abnormally methylated in diploid biparental
molar tissues. They explained their findings by the known
high degree of epigenetic stability and resistance of hESC
lines to perturbations in DNA methylation at imprinted loci
[56]. Conversely, they found that NLRP7 knockdown altered
the DNA methylation of many non-imprinted CpGs. Another
interesting study showed that the DNA methylation of a total
131 imprinted and non-imprinted loci were altered in blood
DNA of an individual with multiple anomalies born to a
mother with a single heterozygous NLRP7 mutation
(A719V) [57]. It would have been interesting in this study to
have determined if the mutation in the mother occurred de
novo or if it was inherited, and from which of her parents. In
addition, it is not clear whether the abnormal child inherited
Fig 2 Suggested screening recommendation for DNA testing and genetic
counselling of patients with recurrent hydatidiformmoles. Patients with at
least two HMs should be offered DNA testing first for NLRP7, in which
mutations are found in 48–80 % of such patients. Among those with two
mutated alleles, up to 7%may have normal live birth (LB) from their own
oocytes in 1.5 % of their pregnancies. To date, three cases of successful
ovum donation have been observed in such patients. Patients without
NLRP7mutations should be tested for KHDC3L, in which mutations are
found in 10–14 % of such patients. For patients with no mutations in
either gene, we propose to re-examine the histopathology of their moles
and determine the parental contribution to them. Patients with confirmed
complete moles that are diploid biparental can be counselled in the same
way as patients with mutations in NLRP7 or KHDC3L. Those with
androgenetic or triploid dispermic moles have higher chances of live
births from their own oocytes andmay be benefit from in vitro fertilization
(IVF) and preimplantation genetic screening (PGS) for aneuploidies
60 Curr Obstet Gynecol Rep (2014) 3:55–64
his mother’s mutation. Surprisingly, comparing the abnormal-
ly methylated genes from the studies by Mahadevan et al. and
Beygo et al. [35•, 57] did not reveal any common gene with
altered methylation, which raise questions about the specific-
ity and significance of these findings and their relation to
NLRP7mutations that remain to be clarified in future studies.
Altered Expression of CDKN1C in the Conceptions
of Patients with NLRP7Mutations
In line with the above data, one study demonstrated the
underexpression of p57KIP2, the product of the paternally
imprinted, maternally expressed gene CDKN1C in the
cytotrophoblast and villous stroma of a series of diploid
biparental CHMs [58]. p57KIP2 is the protein coded by a
cyclin-dependent kinase inhibitor. CDKN1C deficiency in
mice leads to altered cellular proliferation and differentiation,
resulting in a variety of developmental defects [59]. Although
CDKN1C is paternally methylated in the cytotrophoblast and
villous stroma of normal first-trimester placenta, its expression
has been shown to depend on the maternal methylation of
KvDMR1, a CpG island located at the promoter of
KCNQ1OT1 believed to control the imprinted expression of
CDKN1C during embryonic development [60, 61]. The same
is observed in humans, where the loss of maternal methylation
marks at KvDMR1 leads to the silencing of CDKN1C in
patients with Beckwith-Wiedemann syndrome [62], a pediat-
ric overgrowth disorder in which the placenta share some
histopathological features with PHMs.
Despite the complexity of the methylation and imprinting
data and the variations between studies and samples, the
common findings were the lack of DNAmaternal methylation
marks at several maternally imprinted, paternally expressed
genes and the unspecific/stochastic extension of methylation
abnormalities to non-imprinted genes. We believe that further
studies are needed to delineate the exact roles of NLRP7 and




Because of the high rate of NLRP7mutations in patients with
RHMs, which seems to vary with populations, patients with at
least two HMs (complete or partial) should be first offered
NLRP7DNA testing that is now available in many clinical and
research laboratories, including ours. Methods currently in use
rely on PCR amplification of the 11 exons of NLRP7 from
genomic DNA, followed by direct sequencing of the PCR
products in the two directions and the comparison of the
sequences with the reference sequence NM_001127255.1.
This analysis is highly sensitive in identifying point mutations
within the coding region, small deletions and insertions af-
fecting the amplified regions, and DNA changes at the invari-
ant splice sites. However, this method is not reliable to identify
deep intronic single-nucleotide changes affecting the splicing
of the gene or regulatory sequences, large deletions, inser-
tions, and complex rearrangements.
Patients without NLRP7mutations should be screened for
KHDC3L mutations, which account for up to 14 % of cases
who are NLRP7-negative [40•, 41, 63]. Similarly, for
KHDC3L, currently methods rely on PCR amplification of
its 3 exons from genomic DNA, followed by direct sequenc-
ing of the PCR products in the two directions and the com-
parison of the sequences with the reference sequence
NM_001017361. Because of the causal involvement of this
gene in a minority of cases, only some of the laboratories that
offer NLRP7 testing are currently systematically sequencing
KHDC3L for all patients who are NLRP7-negative. The iden-
tification of two defective alleles in either gene allows to
confirm a genetic defect underlying mole recurrence and to
counsel the patients accordingly based on available data in the
field.
Prognosis for Future Pregnancies
The goal of patients seeking DNA testing is to ascertain their
chances of conceiving healthy babies and their risk for mole
recurrence and malignant sequelae. Studies from various
groups have shown that the chances of a normal live birth
are very low in women with two defective alleles in NLRP7.
Among reported patients from our group, only 3 out of 43
(7 %) had normal live births, which accounted for 1.5 % of
their pregnancies. No other cases of live births have been
reported by other groups in patients with RHMs and NLRP7
or KHDC3L mutations, with the exception of a recently de-
scribed case of one live birth to a patient with two defective
alleles in NLRP7 [35•]. In the few reported patients with two
KHDC3L defective alleles, no live birth has been reported.
Based on available data, both genes NLRP7 and KHDC3L
are required in the oocytes. Therefore, theoretically, ovum
donation is expected to improve patients’ reproductive out-
comes. Thus far, few patients with mutations in NLRP7 have
tried ovum donation, and three had normal live births ([64•]
and Slim et al. in preparation), which provides some hope for
patients despite the elevated cost of such procedure and its
inaccessibility for many of them.
For patients with RHMs and no mutations in either gene,
we believe that moles in these patients are most likely to be of
a genetic etiology caused by undetected mutations in either
NLRP7 or KHDC3L or by mutations in non-identified genes.
Based on our current understanding of moles and their mode
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of formation, the best help that can be offered to these patients
is to review the histopathology of their moles and determine
the parental contribution to the molar genomes. Based on the
results of this analysis, the patients may be classified into two
categories:
1. Patients with at least two diploid biparental moles that fit
the histological classification of complete molar pregnan-
cies can be counselled in the same way as patients with
two NLRP7 or KHDC3L mutations despite the lack of
identified mutations. In patients where the histopatholog-
ical re-evaluation disagrees with the diagnosis of moles,
such cases can be counselled similarly to patients with
recurrent spontaneous abortions.
2. Patients with androgenetic or triploid dispermic moles
have higher chances of having live births from their own
oocytes than patients with recurrent diploid biparental
moles. Because androgenetic and triploid dispermic
moles are caused by errors that occur either at the time
of fertilization or very early in the zygote, these patients
may benefit from in vitro fertilization followed by preim-
plantation genetic screening (PGS) to select for diploid
embryos to be transferred to the patients. This option may
not completely prevent having additional moles, but may
help to maximize the patients’ chances of having normal
pregnancies, which should be monitored according to
standard prenatal care for women with recurrent repro-
ductive loss. A chart summarizing our suggested ap-
proach for DNA testing and genetic counselling of pa-
tients with RHMs is provided in Fig. 2.
Risk for Malignant Degeneration
With respect to the risk for malignant degeneration of moles in
patients with mutations in NLRP7 and KHDC3L, we do not
have accurate statistics with regard to their risk as compared to
patients with sporadic common moles. However, available
data on our cases and on those reported by other groups
indicate that despite their higher risk for mole recurrence,
patients with mutations in either gene are at least not at higher
risk for choriocarcinoma. However, future studies are needed
to delineate their risk for the less severe neoplastic degenera-
tion and requirement of chemotherapy.
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